<DOC>
	<DOCNO>NCT01099449</DOCNO>
	<brief_summary>RATIONALE : Chemoprotective drug , calcium gluconate magnesium sulfate , may prevent neurotoxicity cause oxaliplatin . It yet know administration schedule calcium gluconate magnesium sulfate effective preventing neurotoxicity . PURPOSE : This randomized phase III trial study different administration schedule calcium gluconate magnesium sulfate compare well work neurotoxicity patient colon cancer rectal cancer receive oxaliplatin-based combination chemotherapy .</brief_summary>
	<brief_title>Calcium Gluconate Magnesium Sulfate Preventing Neurotoxicity Patients With Colon Cancer Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether 2 schedule calcium gluconate magnesium sulfate infusion ( give chemotherapy chemotherapy ) prevent ameliorate chronic , cumulative oxaliplatin-induced sensory neurotoxicity patient colon rectal cancer receive adjuvant FOLFOX chemotherapy comprise leucovorin calcium , fluorouracil , oxaliplatin . Secondary - To determine whether 2 infusion schedule increase cumulative oxaliplatin dos deliver without dose-limiting chronic neurotoxicity . - To determine whether 2 infusion schedule ameliorate acute neuropathy associate oxaliplatin . - To determine whether 2 infusion schedule cause adverse event . - To investigate whether 2 infusion schedule influence patient quality life . - To describe baseline post-treatment neurological quantitative sensory test abnormality study participant . Tertiary - To explore polymorphisms GSTP1 , GSTM1 , ERCC2 , XRCC1 gene associate early onset oxaliplatin-induced neurotoxicity . OUTLINE : This multicenter study . Patients stratify accord age ( &lt; 65 year vs ≥ 65 year ) , gender , regimen ( FOLFOX4 vs modify FOLFOX6 v ) , stage disease ( II v III v IV ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive calcium gluconate IV magnesium sulfate IV 30 minute immediately oxaliplatin administration ( part FOLFOX chemotherapy comprise leucovorin calcium , fluorouracil , oxaliplatin ) . - Arm II : Patients receive placebo IV 30 minute immediately oxaliplatin administration ( part FOLFOX chemotherapy ) . - Arm III : Patients receive calcium gluconate magnesium sulfate IV 30 minute immediately placebo IV 30 minute immediately oxaliplatin administration ( part FOLFOX chemotherapy ) . In arm , course repeat every 14 day 6 month absence disease progression unacceptable toxicity . Blood sample collect second course treatment translational research . Patients complete questionnaire side effect , quality life , chemotherapy-induced peripheral neuropathy periodically . After completion study treatment , patient follow 3 , 6 , 12 , 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Has undergone curative resection consider stage II III disease completely resect stage IV disease evidence residual tumor Scheduled receive 6 month oxaliplatinbased adjuvant chemotherapy 85 mg/m^2 oxaliplatin every 2 week ( include , instance , FOLFOX4 modify FOLFOX6 ) Patients receive bevacizumab cetuximab combination FOLFOX part clinical trial clinical practice eligible PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Serum creatinine ≤ 1.5 time ULN Serum calcium ≤ 1.2 time ULN Serum magnesium ≤ 1.2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able complete questionnaire ( alone assistance ) Able comply study treatment Willing return enrol institution followup Willing provide blood sample research purpose No preexist peripheral neuropathy grade No family history genetic/familial neuropathy No second third degree AV heart block history second third degree heart block Bundle branch block allow . No medical condition , opinion treat physician , would make protocol unreasonably hazardous patient PRIOR CONCURRENT THERAPY : See Disease Characteristics Central venous access line present , schedule central line place start chemotherapy study treatment No prior treatment neurotoxic chemotherapy ( e.g. , oxaliplatin , cisplatin , taxanes , vinca alkaloid ) No concurrent digitalis medication No concurrent treatment anticonvulsant carbamazepine ( e.g. , Tegretol® ) , phenytoin ( e.g. , Dilantin® ) , valproic acid ( e.g. , Depakene® ) , gabapentin ( Neurontin® ) , pregabalin ( Lyrica® ) No concurrent neurotropic agent , include venlafaxine ( Effexor ) , desvenlafaxine ( Pristiq® ) , milnacipran ( Savella® ) , duloxetine ( Cymbalta ) No concurrent tricyclic antidepressant ( amitryptilline ) , agent specifically give prevent treat neuropathy No concurrent drug give neuroprotectant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>neuropathy</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>